VibroSense Dynamics

The patent application "CIPN Prediction” describes a method and a Biomarker to assess the risk, in different treatment options, to develop permanent nerve damage after completion of treatment. With the patent as a basis, the company's preliminary algorithm can provide doctors with a prognostic tool when choosing different chemotherapy treatments.

 "The CIPN-Prediction patent application is a step in the development of the VibroSense product portfolio within the Oncology business segment. All research is done in collaboration with external partners, which means that the company can simultaneously have full focus on sales in the Diabetes and Occupational Health Care segments", says Hans Wallin, CEO of VibroSense Dynamics AB.

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se

"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet caused by, for example, diabetes, chemotherapy or vibrating hand-held tools. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.

Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.

About the treatment of cancer with chemotherapy
By 2030, an estimated 3 million new cancer cases are expected in Europe, with the majority undergoing treatment regimens involving drugs known to cause chemotherapy-induced peripheral neuropathy (CIPN). Platinum and taxane-based chemotherapies remain foundational in cancer treatments, despite inducing Peripheral Neuropathies in up to 60% of patients.

Although CIPN is a well-known adverse event, it remains underreported and underdiagnosed. Among the drugs associated with CIPN are platinum compounds such as cisplatin, carboplatin and oxaliplatin; taxanes such as paclitaxel and docetaxel; and bortezomib for multiple myeloma. In addition, certain antibodies such as ipilimumab and nivolumab have been linked to neuropathy.

The current standard for evaluating side effects of cancer treatments is Common Terminology Criteria for Adverse Events scale (CTCAE), which assesses peripheral neuropathy on a scale from grade 1 to grade 4. However, the most common method of self-assessment by questionnaire has limitations, especially when it comes to predicting future and long-term side effects.